Bluejay Therapeutics Appoints Mary Cromwell as Senior Vice President and Head of Technical Operations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2025
0mins
Source: Globenewswire
New Leadership Appointment: Bluejay Therapeutics has appointed Dr. Mary Cromwell as Senior Vice President and Head of Technical Operations, bringing over 30 years of experience in biotechnology and a strong background in manufacturing and quality assurance.
Product Development Update: The company's lead candidate, brelovitug (BJT-778), has received FDA Breakthrough Therapy designation for chronic hepatitis delta treatment, alongside previous designations from the EMA.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
